Iqbal Khan steps down as national corporate lead from JSA
Mumbai: Iqbal Khan has stepped down as national corporate lead at JSA Advocates and Solicitors.
Khan joined JSA from Shardul Amarchand Mangaldas in October 2024, along with a team of 18 lawyers, including three retained partners, strengthening mergers, acquisitions and private equity teams in JSA's corporate practice.
"Iqbal Khan has communicated his resignation to JSA. The exit modalities will be worked out mutually keeping in mind the interest of clients, teams involved and the firm,' Vivek Chandy, JSA's managing partner, said in a statement on Wednesday. 'JSA has grown exponentially over the last 18 months and has integrated well with all its lateral partners who are aligned with the culture and values of the firm. The firm will continue to aggressively pursue its growth path and wishes Iqbal well."
Khan's exit comes as top law firms witness mass movement to rivals. He was brought into JSA to work closely with the joint managing partners, practice area chairs, and the executive committee to fortify the firm's corporate practice and augment its range of services.
Prior to joining JSA, he was with Paul Weiss and Kirkland & Ellis in the United States. Khan also holds a J.D. from Columbia Law School (Harlan Fiske Stone Scholar); the Parker School Certificate for Achievement in International and Comparative Law; and LLB from the London School of Economics and Political Science.
He was the editor of the Columbia Journal of European Law and has been ranked as one of the top M&A and private equity lawyers in India by various legal rankings.
Prior to joining JSA, Khan, along with his partners, led deals for clients including Advent, Bain, Brookfield, TPG, Biocon, L&T, LIC, PharmEasy, Reliance, Serum and Tata.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India.com
10 hours ago
- India.com
How Pakistani Scientist's Nuclear Black Market Fuelled Iran's Nuclear Ambitions
New Delhi: Before the world ever saw satellite images of buried centrifuges at Natanz, before the International Atomic Energy Agency (IAEA) dispatched teams to inspect suspicious sites in Fordow and long before Israeli missiles lit up Iranian skies this month, the seeds of Tehran's nuclear capability were already sown. But it happened in Pakistan, Dubai and Kuala Lumpur. At the center of this shadowy nuclear web was Abdul Qadeer Khan – Pakistani metallurgist who, decades ago, stole blueprints from Europe and built Pakistan's atomic bomb. What few could imagine then was that Khan would go on to export that know-how in secret, creating the world's most dangerous underground market for nuclear technology – one that would arm Iran with more than just ambition. Khan began his nuclear journey in the laboratories of Europe in the early 1970s, working for Urenco Group – a Dutch-German-British nuclear consortium. It was there that he accessed and copied sensitive centrifuge designs. By 1975, he returned to Pakistan with a suitcase full of secrets. His role in developing Pakistan's uranium enrichment programme at Kahuta earned him celebrity status at home. But while the world celebrated non-proliferation treaties, he quietly flipped the script. In the 1980s and 1990s, he built a secret pipeline that bypassed governments and treaties. Operating through shell companies, friendly states and willing middlemen, Khan's network smuggled critical nuclear equipment, blueprints and even bomb designs to multiple countries. Iran was one among them. The most consequential sale came in 1987. Iranian officials met intermediaries of Khan's network in Dubai and secured an initial package: centrifuge blueprints, assembly manuals and a roadmap to enrichment. These were based on the P1 and P2 centrifuges – the same models Pakistan used to develop its bomb. In the 1990s, entire sets of components – bellows, rotors, vacuum pumps and high-speed motors – made their way to Iran. Much of the hardware was built in Malaysian factories under Khan's supervision and then disguised and routed through Dubai to avoid detection. By the early 2000s, Iran had a pilot enrichment facility running. The world watched, stunned, as Tehran's capabilities grew faster than intelligence agencies had predicted. But the acceleration was not magic – it was the Khan blueprint at work. Khan's operation was not run out of basements or back alleys. It looked like legitimate business. Precision parts came from Europe and Southeast Asia. Firms like Scomi Precision Engineering in Malaysia manufactured rotors and pipes under the radar. Dubai-based logistics firms repackaged them for discreet delivery to Iran. One of the biggest exposes came in 2003, when U.S. and British forces intercepted a ship bound for Libya. Onboard were centrifuge parts matching Khan's designs. That led to Libya giving up its nuclear program and to the unraveling of the entire network. Investigations by the IAEA and Western intelligence revealed that Khan had sold similar materials to North Korea and Iran. Technical documents recovered from Iranian facilities bore unmistakable Pakistani signatures – even Chinese-style bomb schematics that Khan had allegedly passed along. What Did Iran Really Get? Centrifuge designs: Detailed plans for P1 and P2 centrifuges – blueprints, machining tolerances and assembly procedures. Manufactured parts: From rotors to vacuum systems, thousands of components were delivered over years. Weaponisation docs: Perhaps the most alarming were documents on how to build an implosion-style nuclear weapon. These were not basic concepts, they included measurements, trigger designs and engineering drawings. Technical support: Though no direct evidence exists of Pakistani scientists physically working in Iran, declassified files suggest consistent technical communication and support through intermediaries. The Lasting Impact Even today, Iran's centrifuge models – IR-1 and IR-2 – closely mirror Khan's P1s and P2s. While Iran insists its programme is peaceful, the technological DNA traces directly back to Khan's black-market empire. In 2022, Israeli intelligence leaked documents suggesting that Iran's 'AMAD Plan', an alleged nuclear weapons programme halted in 2003, used Khan-provided blueprints to model bomb designs. The war now raging between Israel and Iran has reignited fears that Tehran's decades-long accumulation of nuclear knowledge may still carry a weapons-grade potential. And while Iran denies any intent to build a bomb, its ability to do so was never entirely homegrown. It was bought, smuggled and built – piece by piece – in the shadows of Abdul Qadeer Khan's legacy.
Time of India
a day ago
- Time of India
Centre extends deadline for revised Schedule M implementation for small, medium pharmas
Mysuru: The Union govt has extended the deadline for implementing the revised Schedule M–Good Manufacturing Practices (GMP)–for small and medium pharmaceutical enterprises (SMEs) with an annual turnover of Rs 250 crore or less, until the end of this year, said Khalid Ahmed Khan, deputy drug controller and president of the Indian Pharmaceutical Association (IPA), Karnataka state branch. He was speaking at the inauguration of a national conference on 'Enhancing Pharmaceutical Quality Assurance through Good Manufacturing Practices (GMP)' and a special session on the Revamped Pharmaceutical Technology Upgradation Assistance Scheme. The event was organised by the PHD Chamber of Commerce and Industry (PHDCCI) health committee in association with the department of pharmaceuticals, Union ministry of chemicals and fertilizers, JSS Academy of Higher Education and Research (JSS AHER) and the IPA Mysuru branch, at the JSS College of Pharmacy on Wednesday. Khan noted that due to the financial burden involved in implementing the revised quality framework, MSME firms were granted time until Dec 2025 to comply. "Firms with turnover above Rs 250 crore, as well as all newly established plants, are required to adopt the revised Schedule M immediately. These guidelines are aligned with WHO and international standards and emphasise total quality management and robust pharmaceutical systems," he added. Khan stressed the importance of leadership and a quality-driven mindset in the pharmaceutical sector. "Even if you're not in a leadership position, you can influence those who are. Without quality, neither the industry nor its workforce can sustain," he said. Dr H Basavana Gowdappa, VC, JSS AHER, commended the department of pharmaceuticals for launching the RPTUAS and urged the industry to treat GMP not as a regulation but a fundamental responsibility. Amaresh Tumbagi, former drug controller of Karnataka, outlined the inspection mechanisms under the revised Schedule M and how regulatory processes have evolved. Dr Pramod Kumar TM, principal, JSS College of Pharmacy, provided insights into current industry regulations and compliance requirements. Jatin Nagpal, joint secretary, PHDCCI, Dharmendra Kumar Yadav, under secretary, department of pharmaceuticals, Yashwant Shinde, manager, SIDBI and Dr Savitha RS, secretary, IPA Mysuru local branch were also present.
The Hindu
2 days ago
- The Hindu
AI in law: Students need to sharpen critical assessment skills to make best use of technology
Generative AI is reshaping the legal industry. AI deployment has changed workflows by streamlining research, drafting, and due diligence while raising important questions around ethics, bias, and the future of legal education. 'Students need to be trained to take up jobs at firms that are keeping up with technological advancements. They need to be taught practical use of AI Tools, like training in legal research, drafting, and knowledge management using AI platforms. They need to sharpen their critical assessment skills to verify AI-generated content, check legal citations, and ensure jurisdictional relevance', says Naval Satarawala Chopra, Partner, SAM. Mr. Chopra says that AI will provide space to lawyers to focus on complex, analytical, and strategic aspects of their work. 'Some routine roles may evolve or diminish, but new opportunities will emerge for those who can harness technology responsibly and creatively. The future legal professional will need to be both technologically adept and deeply grounded in the principles of law and ethics', he says. AI in curriculum For the introduction of AI in law curriculum, institutes need to provide students with practical, hands-on exposure to AI tools. 'Students should be taught not only how to use such technology but also how to critically assess its outputs, verify legal references, and understand the limitations and risks associated with AI-generated content. Embedding these skills early will ensure that graduates are well-prepared for the evolving demands of modern legal practice', says Mr. Chopra. Mr. Chopra also highlights some other important components to be inculcated in law schools, such as data security and privacy. He says students should be taught the ethical and legal obligations around client data and confidentiality when using AI. They also need to explore AI ethics and bias, including algorithmic bias, fairness, and the responsible use of technology. Students adapting to technology while preserving the core principles of legal education requires a balanced approach. It will help to use real-world scenarios to help students understand both the potential and the limitations of AI in legal practice. 'Students must be encouraged to embrace innovation, but also to maintain the analytical rigour, ethical standards, and critical thinking that define the legal profession. Students should understand that technology is taught as a tool to enhance, not replace, foundational legal skills', says Mr. Chopra. AI deployment at law firms Talking about the benefits of the deployment of AI, Mr. Chopra says it can help streamline routine tasks such as contract drafting, document review, and legal research, allowing lawyers to focus on higher-value, strategic work. AI assists in maintaining consistency across documents and helps reduce human error in repetitive tasks. Shardul Amarchand Mangaldas & Co. (SAM) recently announced a firmwide partnership with Harvey, a generative AI platform designed specifically for legal professionals. SAM has implemented Harvey's full suite of AI functionalities across all seven of its offices after a pilot project. Harvey is a Generative AI platform valued at over USD 3 billion, and its shareholders include OpenAI, Sequoia, and Lexis Nexis. It is already being used in the legal industry globally by many, including A&O Shearman, Cravath, Mori Hamada, Gleiss Lutz, and Clifford Chance, as well as other companies, such as KKR and PwC. At SAM, this integration of Harvey's large language model technology into daily practice aims to accelerate contract drafting and review, streamlining due diligence processes, enhancing legal research and predictive analysis, and delivering sharper, data-driven insights for both contentious and advisory matters. To ensure the responsible and effective use of Harvey, SAM implemented a training Program for all the employees. The training covered practical aspects such as prompt engineering, best practices for legal research and drafting with AI, and the importance of data security and confidentiality. The program also emphasised the critical role of human oversight as every AI-generated output is to be subjected to thorough review by qualified lawyers before being incorporated into client work. Mr. Chopra says the firm has implemented some governance protocols to ensure the responsible and secure use of AI. These protocols include: Mandatory human review, which means all AI-generated drafts, research, and summaries must be reviewed and verified by lawyers before being used in client work. The protocols also stress data security and confidentiality. Only firm-approved and licensed AI platforms are used, and sensitive client data is never input into AI tools unless strict security standards are met (such as ISO 27001 and SOC 2 Type 2 certification). The use of personal or unlicensed AI accounts for client work is strictly prohibited. The protocols also mandate that all AI usage is logged and monitored to ensure compliance with internal policies, data privacy laws, and client-specific requirements. For bias and accuracy checks, lawyers are trained to identify and mitigate potential biases or inaccuracies in AI outputs, including the risk of 'hallucinated' legal citations.
